Koers Swedish Orphan Biovitrum AB Xetra
Aandelen
B6E
SE0000872095
Farmaceutische producten
Omzet 2024 * | 25,12 mld. 2,37 mld. 2,18 mld. | Omzet 2025 * | 27,21 mld. 2,57 mld. 2,36 mld. | Marktkapitalisatie | 95,22 mld. 8,99 mld. 8,25 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 4,02 mld. 379 mln. 348 mln. | Nettowinst (verlies) 2025 * | 4,95 mld. 467 mln. 429 mln. | EV/omzet 2024 * | 4,32 x |
Nettoschuld 2024 * | 13,36 mld. 1,26 mld. 1,16 mld. | Nettoschuld 2025 * | 8,81 mld. 832 mln. 764 mln. | EV/omzet 2025 * | 3,82 x |
K/w-verhouding 2024 * |
22,3
x | K/w-verhouding 2025 * |
19
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 50,9% |
Recentste transcriptie over Swedish Orphan Biovitrum AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 22-05-17 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 20-07-18 |
Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 68 | 01-01-21 | |
Annette Clancy
CHM | Chairman | 70 | 08-05-14 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 01-01-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,40% | 101 mld. | |
+8,42% | 42,18 mld. | |
-13,04% | 32,26 mld. | |
+80,80% | 29,79 mld. | |
-10,92% | 16,06 mld. | |
+1,93% | 14,45 mld. | |
-6,77% | 12,01 mld. | |
+177,16% | 10,71 mld. | |
-56,13% | 8,83 mld. |